A phase 2 study of SP1049C, doxorubicin in P-glycoprotein-targeting pluronics, in patients with advanced adenocarcinoma of the esophagus and gastroesophageal junction
The DOI matches its Crossref record; 45 of the 45 references it cites were found in a registry or an index.
Abstract
Purpose To evaluate the antitumor activity of SP1049C, a novel P-glycoprotein targeting micellar formulation of doxorubicin, consisting of doxorubicin and two non-ionic block copolymers (pluronics), in patients with advanced adenocarcinoma of the esophagus and gastroesophageal junction (GEJ). Patients and methods Patients with metastatic or locally advanced unresectable adenocarcinoma of the esophagus or GEJ who had not previously received systemic chemotherapy and had measurable disease were treated with SP1049C 75 mg/m(2) (doxorubicin equivalents) as a brief intravenous infusion every 3 weeks until disease progression or unacceptable toxicity. The primary endpoint was the objective response rate in patients who had received a least one course of SP1049C and had undergone tumor assessment, whereas, secondary endpoints included the objective response rate, progression-free survival (PFS), overall survival, and safety in the intent-to-treat (ITT) population. A review of scans was also conducted post-hoc by a blinded panel of radiologists. Results Twenty-one patients, of which 19 were evaluable for response, were treated with at least one dose of SP1049C. Nine patients had a partial response (PR) and eight patients had either a minor response or stable disease as their best response. The objective response rate was 47% (95% CI: 24.4-71) in the evaluable patient population, whereas the objective response rate was 43% (95% CI: 21.8-65.9) in the ITT population. The post-hoc radiol…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Patients treated with SP1049C at a dose 75 mg/m2 (doxorubicin equivalents) had an objective response rate of 47% in the evaluable patient population, and 43% in the intent-to-treat population along with the median overall survival of 10 months and PFS of 6.6 months.”
From Polymeric micelles for the delivery of poorly soluble drugs: From nanoformulation to clinical approval. (2020) · cites this paper as [10]
In the citing paper
“Since then, many polymeric micelle formulations have reached clinical trials in several countries [9, 10, 300].”
From Polymeric micelles for the delivery of poorly soluble drugs: From nanoformulation to clinical approval. (2020) · cites this paper as [10]
In the citing paper
“Later, a Phase II trial demonstrated that SP1049C has a notable single-agent activity as well as an acceptable safety profile in patients with advanced carcinoma of the esophagus and gastroesophageal junction [10].”
From Polymeric micelles for the delivery of poorly soluble drugs: From nanoformulation to clinical approval. (2020) · cites this paper as [10]
Citations
Cites
1 retracted
Chemotherapy for metastatic carcinoma of the esophagus and gastro-esophageal junction
Homs, M. Y. V., van der Gaast, A., Siersema, P. D., Steyerberg, E. W., & Kuipers, E. J. (2006) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004063.pub2 · Cited by 75
RetractedCancer: Principles and Practice of Oncology.
(1991) · Annals of Internal Medicine · doi:10.7326/0003-4819-114-9-819_4 · Cited by 8,516
Estimates of the cancer incidence and mortality in Europe in 2006
Ferlay, J., Autier, P., Boniol, M., Heanue, M., Colombet, M., & Boyle, P. (2007) · Annals of Oncology · doi:10.1093/annonc/mdl498 · Cited by 4,036
Handbook of Pharmaceutical Excipients
Rowe, R. C., Sheskey, P. J., & Quinn, M. E. (1994) · Cited by 3,493
Symptomatic Gastroesophageal Reflux as a Risk Factor for Esophageal Adenocarcinoma
Lagergren, J., Bergström, R., Lindgren, A., & Nyrén, O. (1999) · New England Journal of Medicine · doi:10.1056/nejm199903183401101 · Cited by 3,020
Rising incidence of adenocarcinoma of the esophagus and gastric cardia
Blot, W. J. (1991) · JAMA · doi:10.1001/jama.265.10.1287 · Cited by 2,354
Capecitabine and Oxaliplatin for Advanced Esophagogastric Cancer
Cunningham, D., Starling, N., Rao, S., Iveson, T., Nicolson, M., Coxon, F., Middleton, G., Daniel, F., Oates, J., & Norman, A. R. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa073149 · Cited by 2,285
Van Cutsem, E., Moiseyenko, V. M., Tjulandin, S., Majlis, A., Constenla, M., Boni, C., Rodrigues, A., Fodor, M., Chao, Y., Voznyi, E., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.06.8429 · Cited by 1,926 · cited 2×
“More recently, the taxanes, have also been demonstrated to be active in esophageal, GEJ/ stomach cancers, and docetaxel has been registered as a component of first-line treatment for advanced gastric/GEJ cancers in many countries [ 13 ].”
BackgroundResultCancer: Principles and Practice of Oncology
Gunn, W. G. (1994) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1994.03510350091047 · Cited by 1,791
Pohl, H., & Welch, H. G. (2005) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/dji024 · Cited by 1,270
Cited by
Kamaly, N., Yameen, B., Wu, J., & Farokhzad, O. C. (2016) · Chemical Reviews · doi:10.1021/acs.chemrev.5b00346 · Cited by 3,070
Nanomedicine in cancer therapy: Challenges, opportunities, and clinical applications
Wicki, A., Witzigmann, D., Balasubramanian, V., & Huwyler, J. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2014.12.030 · Cited by 1,901
Advanced targeted therapies in cancer: Drug nanocarriers, the future of chemotherapy
Pérez-Herrero, E., & Fernández-Medarde, A. (2015) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2015.03.018 · Cited by 1,875
Targeted polymeric therapeutic nanoparticles: design, development and clinical translation
Kamaly, N., Xiao, Z., Valencia, P. M., Radovic-Moreno, A. F., & Farokhzad, O. C. (2012) · Chemical Society Reviews · doi:10.1039/c2cs15344k · Cited by 1,730
Nanoparticle Delivery of Cancer Drugs
Wang, A. Z., Langer, R., & Farokhzad, O. C. (2012) · Annual Review of Medicine · doi:10.1146/annurev-med-040210-162544 · Cited by 1,561
Metadata
- Authors
- Valle, J. W., Armstrong, A., Newman, C., Alakhov, V., Pietrzynski, G., Brewer, J., Campbell, S., Corrie, P., Rowinsky, E. K., & Ranson, M.
- Affiliations
- The Christie Hospital (GB)
- Supratek Pharma (Canada) (CA)
- Addenbrooke's Hospital (GB)
- University of Manchester (GB)
- Corresponding author
- Valle, Juan W.
- Venue
- Investigational New Drugs
- Published
- 2010-02-24
- Volume
- 29
- Issue
- 5
- Pages
- 1029-1037
- ISSN
- 0167-6997 (ISSN-L)
- 1573-0646
- OpenAlex
- W1964185052
- Cited by
- 303
- References
- 45
- Citations by year
- 2026: 8 · 2025: 4 · 2024: 11 · 2023: 14 · 2022: 20 · 2021: 10 · 2020: 29 · 2019: 23 · 2018: 22 · 2017: 23 · 2016: 35 · 2015: 29 · 2014: 23 · 2013: 26 · 2012: 12
- FWCI
- 17.63
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springernature.com/gp/researchers/text-and-data-mining (tdm)
- www.springernature.com/gp/researchers/text-and-data-mining (vor)
- Locations
- Investigational New Drugs (publishedVersion)
- PubMed (publishedVersion)
- Research Explorer (The University of Manchester) (publishedVersion)
- Topics
- Health Sciences › Medicine › Surgery › Esophageal Cancer Research and Treatment
- Health Sciences › Medicine › Oncology › Gastric Cancer Management and Outcomes
- Health Sciences › Medicine › Oncology › Drug Transport and Resistance Mechanisms
- Keywords
- doxorubicin, P-glycoprotein, poloxamer, micellar drug delivery, esophageal adenocarcinoma, gastroesophageal junction adenocarcinoma, advanced adenocarcinoma, objective response rate, progression-free survival, overall survival, neutropenia, cardiotoxicity, anticancer activity
- MeSH terms
- Adenocarcinoma, Adult, Aged, Antineoplastic Agents, Antineoplastic Combined Chemotherapy Protocols, Doxorubicin, Esophageal Neoplasms, Esophagogastric Junction, Female, Humans, Male, Middle Aged, Neoplasm Staging, Stroke Volume, ATP Binding Cassette Transporter, Subfamily B, Member 1, Poloxamer, Kaplan-Meier Estimate, Molecular Targeted Therapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A phase 2 study of SP1049C, doxorubicin in P-glycoprotein-targeting pluronics, in patients with advanced adenocarcinoma of the esophagus and gastroesophageal junction. https://app.cochat.ai/papers/10.1007/s10637-010-9399-1
- The paper
- Valle, J. W., Armstrong, A., Newman, C., Alakhov, V., Pietrzynski, G., Brewer, J., Campbell, S., Corrie, P., Rowinsky, E. K., & Ranson, M. (2011). A phase 2 study of SP1049C, doxorubicin in P-glycoprotein-targeting pluronics, in patients with advanced adenocarcinoma of the esophagus and gastroesophageal junction. Investigational New Drugs. https://doi.org/10.1007/s10637-010-9399-1
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.